AND-34/BCAR3 differs from other NSP homologs in induction of anti-estrogen resistance, cyclin D1 promoter activation and altered breast cancer cell morphology
✍ Scribed by Richard I. Near; Yujun Zhang; Anthony Makkinje; Pierre Vanden Borre; Adam Lerner
- Publisher
- John Wiley and Sons
- Year
- 2007
- Tongue
- English
- Weight
- 422 KB
- Volume
- 212
- Category
- Article
- ISSN
- 0021-9541
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
Over‐expression of AND‐34/BCAR3/NSP2 (BCAR3) or its binding‐partner p130Cas/BCAR1 generates anti‐estrogen resistance in human breast cancer lines. Here, we have compared BCAR3 to two related homologs, NSP1 and NSP3/CHAT/SHEP, with regards to expression, anti‐estrogen resistance, and signaling. BCAR3 is expressed at higher levels in ERα‐negative, mesenchymal, than in ERα‐positive, epithelial, breast cancer cell lines. Characterization of “intermediate” epithelial‐like cell lines with variable ER‐α expression reveals that BCAR3 expression correlates with both mesenchymal and ERα‐negative phenotypes. Levels of the BCAR3/p130Cas complex correlate more strongly with the ERα‐negative, mesenchymal phenotype than levels of either protein alone. NSP1 and NSP3 are expressed at lower levels than BCAR3 and without correlation to ERα/mesenchymal status. Among NSP‐transfectants, only BCAR3 transfectants induce anti‐estrogen resistance and augment transcription of cyclin D1 promoter constructs. Over‐expression of all homologs results in activation of Rac, Cdc42 and Akt, suggesting that these signals are insufficient to induce anti‐estrogen resistance. BCAR3 but not NSP1 nor NSP3 transfectants show altered morphology, transitioning from polygonal cell groups to rounded, single cells with numerous blebs. Whereas stable over‐expression of BCAR3 in MCF‐7 cells does not lead to classic epithelial‐to‐mesenchymal transition, it does result in down‐regulation of cadherin‐mediated adhesion and augmentation of fibronectin expression. These studies suggest that BCAR's ability to induce anti‐estrogen resistance is greater than that of other NSP homologs and may result from altered interaction of breast cancer cells with each other and the extracellular matrix. J. Cell. Physiol. 212:655–665, 2007. © 2007 Wiley‐Liss, Inc.